Takeda Pharmaceutical Co Ltd v. Sun Pharmaceutical Industries Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Takeda Pharmaceutical Company Limited (Japan)
  • Defendant: Sun Pharmaceutical Industries Ltd. (India)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:26-cv-02051, D.N.J., 02/26/2026
• Venue Allegations: Plaintiff Takeda alleges venue is proper in the District of New Jersey because Defendant Sun conducts business in the district, derives substantial revenue from sales there, and the district is a likely destination for the accused generic drug product. The complaint also notes that Sun has previously consented to jurisdiction in the D.N.J. in prior patent cases.
• Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's LIVTENCITY® (maribavir) drug product infringes six U.S. patents covering the compound, its isomers, and specific methods of use.
• Technical Context: The dispute centers on maribavir, an antiviral drug used for treating cytomegalovirus (CMV) infection, a significant complication for patients who have undergone organ or stem cell transplantation.
• Key Procedural History: This action is filed under the Hatch-Waxman Act framework, triggered by Defendant's Paragraph IV certification challenging the patents-in-suit. The complaint notes that this case is related to two other pending cases filed by Takeda against different generic manufacturers (Annora Pharma and Qilu Pharmaceutical) concerning the same patents and drug product.

Case Timeline

Date	Event
2010-10-28	Earliest Priority Date ('632, '169 Patents)
2021-11-19	Earliest Priority Date ('989, '907, '170 Patents)
2022-10-12	Earliest Priority Date ('940 Patent)
2023-06-27	'632 Patent Issued
2025-02-04	'989 Patent Issued
2025-05-13	'940 Patent Issued
2025-10-07	'907 Patent Issued
2025-10-21	'169 Patent Issued
2025-10-21	'170 Patent Issued
2026-01-16	Sun's Notice Letter to Takeda
2026-02-26	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,684,632 (the '632 Patent) - "Maribavir Isomers, Compositions, Methods of Making and Methods of Using," issued June 27, 2023

The Invention Explained

• Problem Addressed: The patent discloses that the therapeutic drug maribavir can convert in vivo (isomerize) into different molecular structures (isomers) that may possess lower biological activity, thereby diluting the effective concentration of the drug and reducing its efficacy Compl. Ex. A, '632 Patent, col. 1:55-2:18 This phenomenon was presented as a potential explanation for a prior maribavir Phase 3 clinical trial failing to meet its primary endpoint '632 Patent, col. 2:19-29
• The Patented Solution: The invention claims to enhance maribavir's therapeutic efficacy by providing methods and compositions to counteract this isomerization. The proposed solutions include specific dosing protocols, such as administering the drug under "fasted conditions," to mitigate the impact of isomerization '632 Patent, col. 3:53-58 The patent also covers the isomers themselves, which can be used as analytical standards to monitor the drug's behavior in the body '632 Patent, col. 4:1-17 '632 Patent, abstract
• Technical Importance: Controlling a drug's molecular stability and isomerization pathways in vivo is a critical factor in pharmaceutical development for ensuring consistent bioavailability and therapeutic effect across a patient population '632 Patent, col. 2:7-18

Key Claims at a Glance

• The complaint asserts infringement of one or more claims of the '632 patent Compl. ¶34 Independent claim 1 is representative of the patent's method-of-use claims.
• Independent Claim 1:
  • A method for treatment of a herpes viral infection in a patient in need thereof;
  • comprising orally administering to said patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound;
  • in an amount of 400 mg twice a day;
  • wherein said patient is a stem cell transplant recipient.

U.S. Patent No. 12,213,989 (the '989 Patent) - "Use of Maribavir in Treatment Regimens," issued February 4, 2025

The Invention Explained

• Problem Addressed: Transplant patients often receive numerous other medications, creating a high potential for drug-drug interactions (DDIs) Compl. Ex. B, '989 Patent, col. 1:24-30 Maribavir is metabolized by, and can affect, the cytochrome P450 (CYP) family of enzymes, particularly CYP3A4. Co-administration with drugs that induce or are processed by CYP3A4 can alter the plasma concentrations of maribavir or the co-administered drug, potentially leading to reduced efficacy or increased toxicity '989 Patent, col. 5:6-14 '989 Patent, col. 6:4-14
• The Patented Solution: The patent describes specific dose-adjustment regimens for maribavir to manage these DDIs. For example, when a patient is also taking a strong CYP3A4 inducer (e.g., certain anticonvulsants like phenytoin or phenobarbital), the invention claims methods of increasing the maribavir dose to compensate for the accelerated metabolism and maintain therapeutic concentrations '989 Patent, abstract '989 Patent, col. 7:1-9
• Technical Importance: Safely managing DDIs is critical in polypharmacy settings, especially for vulnerable populations like transplant recipients, to ensure all drugs remain within their effective and non-toxic therapeutic windows '989 Patent, col. 5:21-29

Key Claims at a Glance

• The complaint asserts infringement of one or more claims of the '989 patent Compl. ¶43 Independent claim 1 is representative of the patent's specific dosing regimens.
• Independent Claim 1:
  • A method of treating cytomegalovirus (CMV) infection in a patient suffering therefrom;
  • the method comprising administering maribavir in an amount of 1200 mg orally twice daily;
  • wherein the patient is a transplant recipient;
  • concomitantly exposed to or receiving an anticonvulsant selected from phenytoin or phenobarbital.

U.S. Patent No. 12,295,940 ('940 Patent) - "Viral Inhibitors, the Synthesis Thereof, and Intermediates Thereto," issued May 13, 2025

• Technology Synopsis: This patent addresses inefficiencies in prior art methods of manufacturing maribavir Compl. Ex. C, '940 Patent, col. 1:63-2:60 The invention discloses improved chemical synthesis routes and intermediates for producing maribavir, claiming to offer a higher combined yield compared to previously known processes '940 Patent, abstract '940 Patent, col. 7:15-18
• Asserted Claims: One or more claims Compl. ¶52
• Accused Features: Sun's ANDA Product, a composition comprising maribavir, is alleged to be made by a process that infringes the '940 patent Compl. ¶52 Compl. ¶54

U.S. Patent No. 12,433,907 ('907 Patent) - "Use of Maribavir in Treatment Regimens," issued October 7, 2025

• Technology Synopsis: This patent, related to the '989 patent, addresses the problem of drug-drug interactions when maribavir is co-administered with other medications in transplant patients Compl. Ex. D, '907 Patent, col. 1:23-29 The invention provides specific dosing regimens and instructions for adjusting maribavir dosage when used with drugs that affect the CYP3A4 metabolic pathway, such as certain anticonvulsants '907 Patent, abstract '907 Patent, col. 2:5-24
• Asserted Claims: One or more claims Compl. ¶61
• Accused Features: The use of Sun's ANDA Product as will be instructed by its label, which is alleged to induce infringement of the claimed methods Compl. ¶61 Compl. ¶63

U.S. Patent No. 12,447,169 ('169 Patent) - "Maribavir Isomers, Compositions, Methods of Making and Methods of Using," issued October 21, 2025

• Technology Synopsis: This patent, related to the '632 patent, addresses the technical problem of maribavir's in vivo isomerization into potentially less effective forms Compl. Ex. E, '169 Patent, col. 1:55-2:18 The invention provides methods, such as administering maribavir under "fasted conditions," and compositions designed to enhance the drug's efficacy by mitigating the effects of this isomerization '169 Patent, abstract
• Asserted Claims: One or more claims Compl. ¶70
• Accused Features: The composition of Sun's ANDA Product and its use as will be instructed by its label Compl. ¶70 Compl. ¶72

U.S. Patent No. 12,447,170 ('170 Patent) - "Use of Maribavir in Treatment Regimens," issued October 21, 2025

• Technology Synopsis: This patent, related to the '989 and '907 patents, addresses drug-drug interactions involving maribavir, particularly in transplant recipients who require multiple concurrent medications Compl. Ex. F, '170 Patent, col. 1:23-29 The invention provides specific methods for treating CMV by co-administering maribavir with immunosuppressants and anticonvulsants, including specific dose adjustments to maintain safety and efficacy '170 Patent, abstract '170 Patent, col. 2:5-24
• Asserted Claims: One or more claims Compl. ¶79
• Accused Features: The use of Sun's ANDA Product as will be instructed by its label, which is alleged to induce infringement of the claimed methods Compl. ¶79 Compl. ¶81

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is "Sun's ANDA Product," identified as 200 mg tablets of maribavir for which Sun seeks FDA approval via ANDA No. 219690 Compl. ¶28

Functionality and Market Context

• The product is intended to be a generic version of Takeda's LIVTENCITY® Compl. ¶32 Its function is as a cytomegalovirus (CMV) pUL97 kinase inhibitor for treating post-transplant CMV infection or disease in patients who are refractory to other antiviral treatments like ganciclovir or foscarnet Compl. ¶10 The complaint alleges that Sun is the "fourth largest specialty generic pharmaceutical company in the world" and that it intends to manufacture, import, and sell its generic product in the United States upon FDA approval Compl. ¶17 Compl. ¶19

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

'632 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for treatment of a herpes viral infection in a patient in need thereof...	Sun's ANDA Product is indicated for the treatment of cytomegalovirus (CMV), a type of herpes virus, in post-transplant patients.	¶10; ¶34	col. 1:30-34
...comprising orally administering to said patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound...	Sun's ANDA Product contains maribavir (the specified compound) in 200 mg oral tablets.	¶28	col. 1:40-45
...in an amount of 400 mg twice a day...	The FDA-approved labeling for LIVTENCITY®, which Sun's label will allegedly copy, instructs a dosage of 400 mg (two 200 mg tablets) administered twice daily.	¶10; ¶13	col. 8:50-52
...wherein said patient is a stem cell transplant recipient.	The product is indicated for post-transplant CMV infection, a population that includes stem cell transplant recipients.	¶10	col. 8:53-54

• Identified Points of Contention:
  • Scope Questions: A potential issue may be whether the instructions in Sun's eventual product label will be found to actively induce physicians to prescribe the drug specifically for "stem cell transplant recipients" as required by the claim, versus a broader "post-transplant" population.
  • Technical Questions: The patent's background emphasizes the importance of "fasted conditions" to mitigate isomerization '632 Patent, col. 2:40-44 The infringement analysis may turn on whether the accused product's label instructs or encourages administration under specific fasting protocols that fall within the scope of other claims in the patent (e.g., claim 3).

'989 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating cytomegalovirus (CMV) infection in a patient suffering therefrom...	Sun's ANDA Product is indicated for the treatment of CMV infection.	¶10; ¶43	col. 1:31-34
...the method comprising administering maribavir in an amount of 1200 mg orally twice daily...	Sun's product label will allegedly instruct physicians on dose adjustments, including a potential increase to 1200 mg when co-administered with certain other drugs, as taught in the patent.	¶13; ¶43	col. 47:10-11
...wherein the patient is a transplant recipient...	The product is indicated for post-transplant patients.	¶10	col. 47:12-13
...concomitantly exposed to or receiving an anticonvulsant selected from phenytoin or phenobarbital.	The product's label will contain information regarding drug-drug interactions, which the complaint alleges will induce physicians to prescribe the claimed 1200 mg dose when the drug is used concomitantly with phenytoin or phenobarbital.	¶13	col. 47:13-15

• Identified Points of Contention:
  • Scope Questions: The infringement allegation is for induced infringement. A central question for the court will be whether the language in Sun's proposed drug label constitutes active encouragement or instruction to perform the specific combination of steps required by claim 1: administering a 1200 mg dose of maribavir specifically when a transplant patient is also taking phenytoin or phenobarbital.
  • Technical Questions: Evidence of infringement will depend on the specific instructions and warnings contained in the final, FDA-approved label for Sun's product concerning dose adjustments in the presence of CYP3A4 inducers.

V. Key Claim Terms for Construction

• The Term: "fasted conditions" (from the '632 patent family, e.g., '632 Patent, claim 3)

• Context and Importance: The specification of the '632 patent posits that administering maribavir under "fasted conditions" was a key differentiator that explained the success of an earlier clinical trial versus the failure of a later one, tying the term directly to the drug's efficacy and the core of the alleged invention '632 Patent, col. 2:40-56 Practitioners may focus on this term because its definition will be critical to determining whether use of the accused product infringes method claims requiring administration under such conditions.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification provides a general definition: "the condition of not having consumed food during the period between from at least about 3 to 12 hours prior to the administration...to at least about 1 to 3 hours after the administration" '632 Patent, col. 5:58-64 This flexible language could support a broad, commonly understood meaning of "fasting."
  • Evidence for a Narrower Interpretation: The specification includes a table with multiple, distinct "Fasting conditions" defined by specific time windows (e.g., "12 hrs/3 hrs," "6 hrs/2 hrs," "3 hrs/1 hr") '632 Patent, col. 5-6, table A defendant may argue that "fasted conditions" should be limited to one of these specific, enumerated protocols rather than a general state of fasting.

• The Term: "therapeutically effective amount" (from the '989 patent family, e.g., '989 Patent, Summary)

• Context and Importance: While a common term, its meaning here is tied to specific, adjusted dosages (e.g., 1200 mg) intended to overcome drug-drug interactions. The central dispute will involve whether prescribing these specific adjusted dosages, as allegedly induced by the accused product's label, constitutes infringement. Practitioners may focus on how this term is defined in the context of the patent's disclosure of specific dose adjustments.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The term is used throughout the specification without an explicit, limiting definition, suggesting it could be given its plain and ordinary meaning as understood in the pharmaceutical arts.
  • Evidence for a Narrower Interpretation: The patent repeatedly links the concept of therapeutic efficacy to specific dose adjustments away from the standard 400 mg dose, such as increasing the dose to 800 mg or 1200 mg to counteract the effect of a CYP3A4 inducer '989 Patent, col. 2:15-20 '989 Patent, col. 7:1-9 This suggests that "therapeutically effective" is not a single value but is context-dependent and defined by the specific dosing regimens disclosed to manage DDIs.

VI. Other Allegations

• Indirect Infringement: Takeda alleges both induced and contributory infringement for all six patents-in-suit. The core of this allegation is that Sun, with knowledge of the patents, will sell its generic product with an FDA-approved label that is substantially similar to the LIVTENCITY® label, and that this label will instruct and encourage physicians and patients to administer the drug in a manner that directly infringes the claimed methods (e.g.,Compl. ¶13, Compl. ¶37, Compl. ¶46). The complaint further alleges the product is especially adapted for these infringing uses and has no substantial non-infringing use (e.g.,Compl. ¶38, Compl. ¶47).
• Willful Infringement: The complaint does not contain a specific count for willful infringement. However, for each patent, it alleges that the case is "an exceptional one" and requests an award of attorneys' fees under 35 U.S.C. § 285 (e.g.,Compl. ¶41). This claim is supported by the allegation that Sun has had knowledge of the patents-in-suit since at least the date of its ANDA submission (e.g.,Compl. ¶39).

VII. Analyst's Conclusion: Key Questions for the Case

• A central question of induced infringement will be whether Sun's future product label, by describing dose adjustments for drug-drug interactions or specific administration protocols, will be found to contain instructions that actively encourage or direct medical providers to perform the patented methods, thus rising to the level of specific intent required for inducement.
• A key issue will be one of claim scope and validity: The patents claim specific methods of using and manufacturing a known compound, maribavir. The case will likely involve significant disputes over whether these claims-particularly those directed to specific dosages (e.g., 400 mg, 800 mg, 1200 mg) and administration conditions (e.g., "fasted," co-administration with other drugs)-are novel and non-obvious over the prior art concerning maribavir's clinical use and known metabolic properties.
• An evidentiary question will be one of technical implementation: For the manufacturing-related patents (e.g., the '940 patent), the dispute may turn on whether Takeda can produce sufficient evidence that the process Sun uses (or will use) to manufacture its generic maribavir product practices the specific, improved synthesis steps claimed in the patent.